Business
EVIO Inc. Announces the Filing of Preliminary Non-Offering Prospectus
EVIO Inc. Announces the Filing of Preliminary Non-Offering Prospectus.
About this update from Evio, Inc.
[{"type":"text","content":"\n\n\n\nEVIO Inc. Announces the Filing of Preliminary Non-Offering Prospectus\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nEVIO Inc. Announces the Filing of Preliminary Non-Offering Prospectus\nPR Newswire\nBEND, Ore., July 2, 2018\n\n\n\nBEND, Ore., July 2, 2018 /PRNewswire/ -- EVIO Inc. (\"EVIO\" or the \"Company\"), (OTCQB: EVIO), a leading provider of cannabis testing and scientific research for the regulated cannabis industry in North America, is pleased to announce it has filed and obtained a receipt for its preliminary non-offering prospectus (\"Preliminary Prospectus\") with the Ontario Securities Commission (the \"OSC\"). The filing is required for EVIO to qualify in becoming a reporting issuer in Ontario, Canada. The Preliminary Prospectus contains important information relating to EVIO and its currently issued securities and is subject to amendment as may be required by the OSC. Once the OSC has completed its review and provided its comments to the Preliminary Prospectus, the Company will proceed with filing its non-offering (final) prospectus (\"Final Prospectus\") with the OSC. Once the Company receives the final receipt for the Final Prospectus, the Company will apply to have its common shares listed on the Canadian Securities Exchange. \n\n\n \n \n\n \nCopies of the preliminary prospectus are available on SEDAR at http://www.sedar.com under EVIO's SEDAR profile. \n\nAbout EVIO Inc.EVIO Inc. is a leading provider of cannabis testing and scientific research for the regulated cannabis industry. The Company's EVIO Labs division operates coast-to-coast providing state-mandated ancillary services to ensure the safety and quality of the nation's cannabis supply.  The Company's EVIO Biosciences Division is dedicated to the scientific, medical, and psychosocial exploration of clinical cannabis, cannabinoids, and the endocannabinoid system. For more information, visit www.eviolabs.com.\n\nSafe Harbor StatementAny statements in this press release that are not statements of historical fact maybe considered to be forward-looking statements. State...